Why biopharma growth is essential, Pg14

Key Highlights:

• Biological therapies have revolutionized treatment for diseases like cancer, asthma and rheumatoid arthritis.
• High costs limit access to these therapies for most Indians.
• Biosimilars offer a more affordable alternative, but their development in India has lagged.
• Biopharma Shakti aims to transform India into a biopharmaceutical hub.
• Successful implementation requires investment in skills, quality systems, and innovation.

Detailed Insights:

• Biological therapies are more precise and less toxic than traditional chemical drugs, leading to better outcomes.
• India's pharmaceutical industry has excelled in generic drugs but needs to strengthen its biopharmaceutical sector.
• Biosimilars, while not exact copies of biologics, can provide the same clinical benefits at a lower cost if rigorously developed and regulated.
• Biopharma Shakti addresses structural barriers by strengthening research, clinical trials, regulatory expertise, and manufacturing infrastructure.
• Mission-mode execution, similar to ISRO's approach, is crucial for Biopharma Shakti's success, requiring collaboration among stakeholders.
• Investment in skills and quality systems is essential for biologics manufacturing, which demands high precision and quality control.
• A thriving biosimilar ecosystem should foster both affordability and original biologic innovation, bridging the gap between current accessibility and future advancements.

Key Concepts Involved:

• Biological Therapies (Biologics): Medicines derived from living systems, targeting specific disease pathways.
• Biosimilars: Drugs similar to original biologic medicines, offering comparable clinical benefits at lower costs.
• Biopharma Shakti: Indian government initiative to promote biopharmaceutical manufacturing and innovation.